ProfileGDS5678 / 1416155_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 88% 86% 87% 86% 86% 80% 84% 84% 88% 90% 89% 90% 90% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.788788
GSM967853U87-EV human glioblastoma xenograft - Control 26.5785986
GSM967854U87-EV human glioblastoma xenograft - Control 36.7447987
GSM967855U87-EV human glioblastoma xenograft - Control 46.7098386
GSM967856U87-EV human glioblastoma xenograft - Control 56.5771286
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4284780
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0143484
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.1834884
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.7968288
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.2393590
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.0640589
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3321590
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.2306490
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1503790